Bio-Rad Laboratories, Inc. develops, manufactures, and markets a broad range of products and solutions for the life science research and clinical diagnostics markets. Technologies and applications include electrophoresis, imaging, multiplex immunoassay, chromatography, microbiology, protein function analysis, transfection, flow cytometry and cell sorting, amplification, and real-time and digital PCR.
Bio-Rad is an in-vitro diagnostics supplier, delivering a large portfolio of innovative products to clinical laboratories worldwide. Also the Company is a leader in clinical quality control products, services, and information systems. These products ensure the accuracy and validity of clinical test results and are used by more clinical laboratories than products from any other company. Its other diagnostic products and systems leverage a broad range of technologies and deliver high-value clinical
information in the blood transfusion, diabetes monitoring, autoimmune, and infectious disease testing markets and are used to support the diagnosis, monitoring, and treatment of diseases and other medical conditions.
Company Growth (employees)
Bio-Rad Office Locations
Bio-Rad Data and Metrics
Bio-Rad Financial Metrics
Revenue (Q1, 2017) | 500.1 m |
Gross profit (Q1, 2017) | 270 m |
Gross profit margin (Q1, 2017), % | 54% |
Net income (Q1, 2017) | 12.4 m |
Market capitalization (21-Sep-2017) | 6.9 b |
Cash (31-Mar-2017) | 291.7 m |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 2.1 b | 2.2 b | 2 b | 2.1 b |
Revenue growth, % | 2% | (7%) | 2% | |
Cost of goods sold | 897.8 m | 930.1 m | ||
Gross profit | 1.1 b | 1.1 b |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 536.8 m | 530.6 m | 472.8 m | 506.1 m | 470 m | 471.2 m | 516.8 m | 508.7 m | 500.1 m |
Cost of goods sold | 239.6 m | 242.1 m | 202.7 m | 226.5 m | 206.5 m | 207.2 m | 236.5 m | 229.3 m | 230.1 m |
Gross profit | 297.2 m | 288.6 m | 270.1 m | 279.6 m | 263.5 m | 264 m | 280.2 m | 279.5 m | 270 m |
Gross profit Margin, % | 55% | 54% | 57% | 55% | 56% | 56% | 54% | 55% | 54% |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 331.6 m | 413.3 m | 457.5 m | 456.3 m |
Inventories | 525 m | |||
Current Assets | 1.7 b | 1.7 b | 1.8 b | 1.8 b |
PP&E | 429.4 m | 428.8 m | 437.7 m | 488.6 m |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 384.7 m | 424.6 m | 425.7 m | 450.1 m | 507.3 m | 403.6 m | 418.7 m | 417.9 m | 291.7 m |
Accounts Receivable | 378.9 m | 354.4 m | 342.2 m | 354.2 m | 341.5 m | 381.1 m | 366.3 m | 367.7 m | 373.4 m |
Inventories | 520.6 m | 516 m | 478.4 m | 501 m | 512.7 m | 533.3 m | 541.5 m | 556.4 m | 559.8 m |
Current Assets | 1.8 b | 1.8 b | 1.7 b | 1.7 b | 1.8 b | 1.8 b | 1.8 b | 1.9 b | 1.7 b |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | 77.8 m | 88.8 m | 113.1 m | |
Cash From Operating Activities | 175.5 m | 273.3 m | 186.2 m | 216.4 m |
Capital Expenditures | (113 m) | (121 m) | (112 m) | (141.4 m) |
Cash From Investing Activities | (5.4 m) | (190.5 m) | (166.9 m) | (213.9 m) |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | 31.6 m | 11.5 m | 17.8 m | 28.4 m | 17.4 m | 12.3 m | 30.3 m | 48.7 m | 12.4 m |
Accounts Receivable | 378.9 m | 354.4 m | 342.2 m | 354.2 m | 341.5 m | 381.1 m | 366.3 m | 367.7 m | 373.4 m |
Accounts Payable | 125.5 m | 126.6 m |
| USD | Y, 2017 |
|---|---|
Revenue/Employee | 60.6 k |
Financial Leverage | 1.5 x |
